

Remarks/Arguments

This is in response to the requirement for restriction mailed July 9, 2004. In a telephonic interview with the Examiner on August 26, 2004, the claims were discussed. Applicants' representative proposed that the claims be amended to limit claims 1 and 22 to compounds of Formula II, and to further limit the compounds to not more than nine (9) named compounds.

The instant amendment to claims 1 and 22 provide for only compounds represented by Formula II, and specifically name seven (7) compounds from that generic formula. Applicants believe that independent claims 1 and 22, as amended, represent a reasonable number of compounds for purposes of prosecution on the merits. Applicants' representative further believes that this amendment is consistent with the agreed upon restriction of the instant claims, discussed on August 26, 2004. If the Examiner believes that further discussion would aid in the advancement of this application, she is urged to contact applicants' representative at the phone number listed below.

In addition, claim 37 has been amended to correct a typographical error in the dependency of the claim.

Respectfully submitted,



Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, Missouri 63006

Philip B. Polster II
Reg. No. 43,864
(314) 274-9094
(314) 274-9095 (facsimile)